Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Venetoclax clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Venetoclax as a study intervention. Browse Venetoclax recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
465
Shown on this page
12
Current sort
Recently updated
Therapy scope
Venetoclax
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Venetoclax. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 145–156 of 465 matching trials for Venetoclax.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 1Phase 2 Interventional

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

NCT07311746
View directory record Official record
Conditions
T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia
Interventions
Ruxolitinib, Cladribine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 28, 2026, 6:00 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

NCT04708054
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
Busulfan, Cladribine, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Thiotepa, Venetoclax
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 28, 2026, 6:00 AM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

NCT02756897
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Venetoclax
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 28, 2026, 6:00 AM EDT
Recruiting Phase 2 Interventional

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

NCT06390319
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
Interventions
Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Dasatinib, Venetoclax, Bortezomib, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Methotrexate, Thioguanine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
4
States / cities
San Diego, California • Charlotte, North Carolina • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 28, 2026, 6:00 AM EDT
Active, not recruiting Phase 2 Interventional

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

NCT02846623
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
Interventions
Atezolizumab, Laboratory Biomarker Analysis, Obinutuzumab, Venetoclax
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 28, 2026, 6:00 AM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT03946878
View directory record Official record
Conditions
Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive, CD5 Positive, FCER2 Negative, Pleomorphic Variant Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, t(11;14)(q13;q32)
Interventions
Acalabrutinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 28, 2026, 6:00 AM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

NCT03128879
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Ibrutinib, Venetoclax, Acalabrutinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 28, 2026, 6:00 AM EDT
Completed Phase 2 Interventional Results available

Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia

NCT03573024
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Venetoclax
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 59 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 28, 2026, 6:00 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

NCT06456463
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Tagraxofusp, Venetoclax, Azacitidine
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
24
States / cities
Los Angeles, California • Stanford, California • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 28, 2026, 6:00 AM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501
View directory record Official record
Conditions
Hematologic Cancer
Interventions
ABBV-101, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 28, 2026, 6:00 AM EDT
Active, not recruiting Phase 2 Interventional Results available

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

NCT04284787
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
Interventions
Azacitidine, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab, Venetoclax
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
29
States / cities
Greenwich, Connecticut • Hartford, Connecticut • New Haven, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 28, 2026, 6:00 AM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

NCT04847453
View directory record Official record
Conditions
Recurrent AL Amyloidosis, Refractory AL Amyloidosis
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Dexamethasone, Echocardiography Test, Ixazomib Citrate, Magnetic Resonance Imaging, Positron Emission Tomography, Transabdominal Ultrasound, Venetoclax, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
16
States / cities
Duarte, California • Sacramento, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 28, 2026, 6:00 AM EDT

About this Venetoclax clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Venetoclax as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Venetoclax.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Venetoclax.